interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Selinexor

Generic competition · all medicines · read 12 November 2026

Is there a generic of Selinexor, and who makes it?

Selinexor appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Selinexor1 dosage-form group in the Orange Book
0generic makers listed
  1. Selinexor appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Xpovio. No generic is listed as marketed.

2015202020252030203501brand 2019data datePatent 11787771 listed to expire 26 July 2032Patent 9079865 listed to expire 26 July 2032Patent 10544108 listed to expire 26 July 2032Patent 11034660 listed to expire 26 July 2032Patent 12291508 listed to expire 26 July 2032Patent 9714226 listed to expire 26 July 2032Patent 8999996 listed to expire 3 July 2033Patent 10519139 listed to expire 14 August 2035Patent 11746102 listed to expire 14 August 2035Patent 11753401 listed to expire 14 August 2035Patent 11807629 listed to expire 14 August 2035Exclusivity ODE* to 22 June 2027Exclusivity ODE-310 to 22 June 2027Exclusivity ODE* to 18 December 2027Exclusivity ODE-346 to 18 December 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 22 June 2027Exclusivity ODE* Xpovio
  • 22 June 2027Exclusivity ODE-310 Xpovio
  • 18 December 2027Exclusivity ODE* Xpovio
  • 18 December 2027Exclusivity ODE-346 Xpovio
  • 26 July 2032Patent 11787771
  • 26 July 2032Patent 9079865
  • 26 July 2032Patent 10544108
  • 26 July 2032Patent 11034660
  • 26 July 2032Patent 12291508
  • 26 July 2032Patent 9714226 drug substance
  • 3 July 2033Patent 8999996 drug substance
  • 14 August 2035Patent 10519139 drug substance

3 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.